Carcinoid Tumors, Intestinal disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

ICT MCID: CRC014 MIFTS: 48	Carcinoid Tumors, Intestinal (ICT) Categories: Cancer diseases, Gastrointestinal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Carcinoid Tumors, Intestinal

MalaCards integrated aliases for Carcinoid Tumors, Intestinal:

Name: Carcinoid Tumors, Intestinal ⁵⁷ ¹² ⁵

Gastrointestinal Carcinoid Tumor ⁷³ ⁵³ ⁷¹

Argentaffinoma ⁷³ ⁷¹

Carcinoid ⁷³ ⁵³

Carcinoid Tumor No Icd-O Subtype ⁷¹

Malignant Carcinoid Syndrome ⁷¹

Tumor, Carcinoid, Intestinal ³⁸

Carcinoid Tumor of Intestine ⁷¹

Intestinal Carcinoid Tumor ⁷³

Carcinoid Tumor ⁷¹

Ict ⁷³

Characteristics:

Inheritance:

Autosomal dominant ⁵⁷

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM® ⁵⁷ 114900

MeSH ⁴³ D002276

MedGen ⁴⁰ C0349535

UMLS ⁷¹ C0007095 C0024586 C0220620 more

Sources

Summaries for Carcinoid Tumors, Intestinal

UniProtKB/Swiss-Prot: ⁷³ A yellow, well-differentiated, circumscribed tumor that arises from enterochromaffin cells in the small intestine or, less frequently, in other parts of the gastrointestinal tract.

MalaCards based summary: Carcinoid Tumors, Intestinal, also known as gastrointestinal carcinoid tumor, is related to goblet cell carcinoid and appendix carcinoid tumor. An important gene associated with Carcinoid Tumors, Intestinal is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways is Neuroscience. The drugs Histamine and Cyproheptadine have been mentioned in the context of this disorder. Affiliated tissues include small intestine, lung and appendix, and related phenotypes are intestinal carcinoid and nervous system

More information from OMIM: 114900

Sources

Related Diseases for Carcinoid Tumors, Intestinal

Diseases related to Carcinoid Tumors, Intestinal via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1286)

#	Related Disease	Score	Top Affiliating Genes
1	goblet cell carcinoid	32.7	ENO2 CHGA
2	appendix carcinoid tumor	31.9	SYP ENO2 CHGA
3	appendix adenocarcinoma	31.7	SYP CHGA
4	pulmonary blastoma	31.3	SYP NKX2-1 CHGA
5	rectum neuroendocrine neoplasm	31.2	SYP SST GAST
6	gastritis	30.9	SST GAST CHGA
7	mature teratoma	30.8	SYP ENO2
8	serotonin syndrome	30.8	SST NOTCH1 MEN1 GAST CHGA
9	lung benign neoplasm	30.7	SYP NKX2-1 ENO2 CHGA
10	pernicious anemia	30.7	SST GAST CHGA
11	pulmonary valve insufficiency	30.6	SST CHGA
12	somatostatinoma	30.6	SSTR2 SST MEN1 GAST ENO2 CHGA
13	small cell carcinoma	30.5	SYP NKX2-1 ENO2 CHGA
14	cystic teratoma	30.5	SYP NKX2-1 ENO2 CHGA
15	benign teratoma	30.5	SYP NKX2-1 ENO2 CHGA
16	carcinoid syndrome	30.5	SYP SST ENO2 CHGA
17	autoimmune gastritis	30.5	GAST CHGA
18	struma ovarii	30.4	SYP NKX2-1
19	atrophic gastritis	30.4	SST MEN1 GAST CHGA
20	lung oat cell carcinoma	30.3	SYP ENO2 CHGA
21	mediastinal cancer	30.3	SYP NKX2-1 ENO2 CHGA
22	zollinger-ellison syndrome	30.3	SST MEN1 GAST CHGA
23	neurofibromatosis, type i	30.3	SST MEN1 ENO2
24	obstructive jaundice	30.2	SYP SST
25	ectopic cushing syndrome	30.2	SYP SST CHGA
26	endocrine gland cancer	30.2	SYP SST GAST CHGA
27	tricuspid valve stenosis	30.1	SST CHGA
28	pulmonary sclerosing hemangioma	30.1	SYP NKX2-1 CHGA
29	secretory diarrhea	30.0	SST GAST
30	orbital cancer	30.0	SYP ENO2
31	sclerosing hemangioma	30.0	SYP NKX2-1 CHGA
32	tubular adenocarcinoma	30.0	SYP ENO2 CHGA
33	glomus tumor	30.0	SYP ENO2
34	neuroendocrine carcinoma	30.0	SYP SST NOTCH1 NKX2-1 MEN1 GAST
35	middle ear adenoma	30.0	SYP ENO2 CHGA
36	ampulla of vater benign neoplasm	30.0	SYP SST ENO2 CHGA
37	dumping syndrome	29.9	SST GAST
38	suppression of tumorigenicity 12	29.9	SYP ENO2 CHGA
39	sertoli-leydig cell tumor	29.9	SYP ENO2
40	peptic ulcer disease	29.9	SST MEN1 GAST
41	patent foramen ovale	29.9	SST NKX2-1 CHGA
42	pituitary adenoma	29.9	SSTR2 SST MEN1 CHGA
43	pituitary tumors	29.9	SST MEN1
44	malignant teratoma	29.9	SYP ENO2
45	acinar cell carcinoma	29.9	SYP GAST CHGA
46	hypoglycemia	29.8	SST GAST CHGA
47	pineocytoma	29.8	SYP ENO2 CHGA
48	jejunal neoplasm	29.8	SYP ENO2
49	mature teratoma of the ovary	29.8	SYP ENO2
50	ewing sarcoma	29.8	SYP ENO2 CHGA

Graphical network of the top 20 diseases related to Carcinoid Tumors, Intestinal:

Sources

Symptoms & Phenotypes for Carcinoid Tumors, Intestinal

Human phenotypes related to Carcinoid Tumors, Intestinal:

³⁰

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	intestinal carcinoid ³⁰			HP:0006723

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Oncology:
intestinal carcinoid
appendiceal carcinoid
malignant carcinoid of ileum

Clinical features from OMIM®:

114900 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Carcinoid Tumors, Intestinal:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	9.61	CHGA CHGB ENO2 MEN1 NKX2-1 NOTCH1
2	digestive/alimentary	MP:0005381	9.1	GAST MEN1 NKX2-1 NOTCH1 SST SSTR2

Sources

Drugs & Therapeutics for Carcinoid Tumors, Intestinal

Drugs for Carcinoid Tumors, Intestinal (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Histamine

Approved, Investigational

Phase 3

51-45-6

774

Cyproheptadine

Approved

Phase 3

129-03-3

2913

Bevacizumab

Approved, Investigational

Phase 2, Phase 3

216974-75-3

135329020

Levoleucovorin

Approved, Experimental, Investigational

Phase 2, Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Fluorouracil

Approved

Phase 2, Phase 3

51-21-8

3385

Oxaliplatin

Approved, Investigational

Phase 2, Phase 3

61825-94-3

43805 11947679 6857599

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2, Phase 3

59-30-3

6037

3-Iodobenzylguanidine

Phase 3

Immunoglobulins, Intravenous

Phase 3

Immunoglobulins

Phase 3

Antibodies, Monoclonal

Phase 3

Antibodies

Phase 3

Mitogens

Phase 3

Immunoglobulin G

Phase 3

Endothelial Growth Factors

Phase 3

Dermatologic Agents

Phase 3

Gastrointestinal Agents

Phase 3

Histamine phosphate

Phase 3

51-74-1

134614

Anti-Allergic Agents

Phase 3

Histamine H1 Antagonists

Phase 3

Histamine Antagonists

Phase 3

Angiogenesis Inhibitors

Phase 2, Phase 3

Immunosuppressive Agents

Phase 2, Phase 3

Vitamins

Phase 2, Phase 3

Folate

Phase 2, Phase 3

Vitamin B9

Phase 2, Phase 3

Trace Elements

Phase 2, Phase 3

Vitamin B Complex

Phase 2, Phase 3

Antidotes

Phase 2, Phase 3

Micronutrients

Phase 2, Phase 3

Protective Agents

Phase 2, Phase 3

Hormone Antagonists

Phase 3

Neurotransmitter Agents

Phase 3

5-Hydroxytryptophan

Phase 3

Serotonin Receptor Agonists

Phase 3

Serotonin

Investigational, Nutraceutical

Phase 3

50-67-9

5202

Lactitol

Approved, Investigational

Phase 1, Phase 2

585-86-4

157355

Peginterferon alfa-2b

Approved

Phase 2

215647-85-1, 99210-65-8

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Hydroxyurea

Approved

Phase 2

127-07-1

3657

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Streptozocin

Approved, Investigational

Phase 2

18883-66-4, 66395-18-4

29327

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Floxuridine

Approved

Phase 2

50-91-9

5790

Axitinib

Approved, Investigational

Phase 2

319460-85-0

6450551

Interventional clinical trials:

(show top 50) (show all 163)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase IV, International, Open-label, Randomised, Cross-over Study to Assess Patient Preference and Health Economy in Patients With Neuroendocrine Tumours, Treated With Lanreotide Autogel Given as Self Administration.	Completed	NCT00681187	Phase 4	lanreotide (Autogel formulation)
2	Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation A Prospective Interventional Trial of Patients With Neuro-endocrine Tumors With Carcinoid Syndrome Receiving Octreotide LAR	Terminated	NCT04140409	Phase 4	Sandostatin
3	123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors	Unknown status	NCT01373736	Phase 3	123I-meta-iodobenzylguanidine
4	A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo	Completed	NCT00412061	Phase 3	Octreotide;Placebo;Everolimus
5	A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)	Completed	NCT02026063	Phase 3	Telotristat etiprate
6	A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome	Completed	NCT00774930	Phase 3	Lanreotide;Placebo
7	A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome	Completed	NCT02063659	Phase 3	Telotristat etiprate;Placebo
8	A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy	Completed	NCT01677910	Phase 3	Telotristat etiprate;Placebo-matching telotristat etiprate
9	A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-related Symptoms Are Inadequately Controlled by Somatostatin Analogues.	Completed	NCT00690430	Phase 3	Pasireotide;Octreotide
10	A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours	Completed	NCT01578239	Phase 3	Octreotide LAR;177Lu-DOTA0-Tyr3-Octreotate
11	Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET)	Recruiting	NCT03375320	Phase 3	Cabozantinib S-malate
12	Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients	Active, not recruiting	NCT00569127	Phase 3	Octreotide Acetate
13	Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial	Not yet recruiting	NCT04820751	Phase 3	Cyproheptadine Hydrochloride 4 MG
14	A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors	Terminated	NCT00227617	Phase 2, Phase 3	5-fluorouracil;leucovorin;oxaliplatin
15	A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome	Terminated	NCT00092287	Phase 3	lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
16	Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion	Terminated	NCT00227136	Phase 3	5-Hydroxy-Tryptamine
17	Randomized Phase III Clinical Trial of Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome	Withdrawn	NCT04065165	Phase 3	Telotristat Ethyl;Lanreotide
18	Carcinoid Tumors After Failure of Somatostatin Analogs: a Randomized Phase III of Octreotide Lutate Peptid Receptor Radionuclide Therapy (PRRT) Versus Interferon α-2b	Withdrawn	NCT01860742	Phase 3	Interferon alpha-2b;177Lu-DOTATATE
19	68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors	Unknown status	NCT02038738	Phase 1, Phase 2	68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
20	A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS	Unknown status	NCT01731925	Phase 2	Lanreotide;Placebo (for sunitinib);Sunitinib
21	A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor	Unknown status	NCT01175096	Phase 1, Phase 2	RAD001 (everolimus, Afinitor®)
22	Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors	Completed	NCT00055809	Phase 2
23	Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors	Completed	NCT02259725	Phase 2	regorafenib
24	A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors	Completed	NCT00131911	Phase 2	sorafenib tosylate
25	A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors	Completed	NCT00075439	Phase 2	gefitinib
26	A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas	Completed	NCT00093782	Phase 2	temsirolimus
27	A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors	Completed	NCT00427349	Phase 2	AMG 706;octreotide
28	Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors	Completed	NCT00416767	Phase 2	fluorouracil;irinotecan hydrochloride;leucovorin calcium
29	Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer	Completed	NCT00019474	Phase 2	fluorouracil;hydroxyurea
30	Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors	Completed	NCT00017199	Phase 2	bortezomib
31	A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy	Completed	NCT00004911	Phase 1, Phase 2
32	A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy	Completed	NCT00004910	Phase 1, Phase 2
33	A Phase II Study of Protracted Infusional 5-Fluorouracil Plus Alpha Interferon for Advanced Metastatic Carcinoid	Completed	NCT00002470	Phase 2	fluorouracil
34	A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors	Completed	NCT00602082	Phase 2	capecitabine;cisplatin;streptozocin
35	Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers)	Completed	NCT00027638	Phase 2	thalidomide
36	Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies	Completed	NCT00005049	Phase 2	carboplatin;cisplatin;floxuridine
37	A Phase 2 Study Evaluating a Proprietary Amino Acid Based Medical Food (Enterade®) in Patients With Quality of Life Limiting Diarrhea Due to Carcinoid Syndrome and Other Neuroendocrine Tumors (NET).	Completed	NCT03722511	Phase 2
38	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multidose Study To Determine Safety and Tolerability of Orally Administered LX1606 in Subjects With Symptomatic Carcinoid Syndrome Refractory to Stable-Dose Octreotide Long-Acting Release Depot Therapy	Completed	NCT00853047	Phase 2	Telotristat etiprate;Octreotide LAR Depot;Placebo
39	A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma	Completed	NCT00454363	Phase 2	Pazopanib Hydrochloride
40	A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer	Completed	NCT01010126	Phase 2	Temsirolimus
41	A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome	Completed	NCT01104415	Phase 2	Telotristat etiprate
42	A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma	Completed	NCT00781911	Phase 2	depot octreotide
43	A Ph 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET Neuroendocrine Tumors/Carcinoid With Elevated Biomarkers	Completed	NCT02132468	Phase 2	fosbretabulin tromethamine
44	Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors	Completed	NCT02575300	Phase 2	Ibrutinib
45	A Phase 1-2 Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With rhuMAb VEGF (Bevacizumab) in Patients With Locally Advanced or Metastatic Carcinoid Tumors	Completed	NCT00328497	Phase 2	Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
46	Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell)	Completed	NCT00113360	Phase 2	RAD001;Octreotide Depot
47	A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors	Completed	NCT01024387	Phase 2	AMG 479
48	An Open-label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Twice Daily Dosing of SOM230 in Patients With Metastatic Carcinoid Tumors	Completed	NCT00088595	Phase 2	Pasireotide (SOM230)
49	EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors	Completed	NCT00050349	Phase 2	EPO906 epothilone B
50	A Phase II Study of Axitinib in Advanced Carcinoid Tumors	Completed	NCT01435122	Phase 2	Axitinib

Search NIH Clinical Center for Carcinoid Tumors, Intestinal

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Interferon Alfa-2b

Sources

Genetic Tests for Carcinoid Tumors, Intestinal

Sources

Anatomical Context for Carcinoid Tumors, Intestinal

Organs/tissues related to Carcinoid Tumors, Intestinal:

MalaCards : Small Intestine, Lung, Appendix, Heart, Liver, Thymus, Lymph Node

Sources

Publications for Carcinoid Tumors, Intestinal

Articles related to Carcinoid Tumors, Intestinal:

(show top 50) (show all 14730)

#	Title	Authors	PMID	Year
1	Complete maternal isodisomy of chromosome 8 in an individual with an early-onset ileal carcinoid tumor. ⁶² ⁵⁷	Karanjawala ZE...Collins FS	10925383	2000
2	Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. ⁶² ⁵⁷	Debelenko LV...Emmert-Buck MR	9361035	1997
3	Familial occurrence of metastasizing carcinoid tumors. ⁶² ⁵⁷	Moertel CG...Dockerty MB	4694894	1973
4	A familial instance of appendiceal carcinoid. ⁶² ⁵⁷	Anderson RE	5936207	1966
5	Prophylactic cholecystectomy in midgut carcinoid patients. ⁵³ ⁶²	Norlen O...Hellman P	20130865	2010
6	PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. ⁵³ ⁶²	Long KB...Hornick JL	20414099	2010
7	Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung. ⁵³ ⁶²	Buonerba C...Marinelli A	20075713	2010
8	Pure red-cell aplasia as the presenting feature of the carcionoid tumor of the thymus: case report. ⁵³ ⁶²	Petakov SM...Damjanovic S	19224408	2010
9	MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype. ⁵³ ⁶²	Chen JY...Chen H	19765735	2010
10	Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. ⁵³ ⁶²	Modlin IM...Gustafsson BI	19845567	2010
11	[Somatostatin receptor scintigraphy in pediatric bronchial carcinoid tumor]. ⁵³ ⁶²	Hervas Benito I...Mateo Navarro A	19819594	2010
12	Primary liver carcinoid tumour with a Zollinger Ellison syndrome - an unusual diagnosis: a case report. ⁵³ ⁶²	Rascarachi G...Olcoz JL	19918579	2009
13	Primary ovarian carcinoid tumor with luteinized stromal cells. ⁵³ ⁶²	Engohan-Aloghe C...Noel JC	19039598	2009
14	Synchronous primary carcinoid tumor and primary adenocarcinoma arising within mature cystic teratoma of horseshoe kidney: a unique case report and review of the literature. ⁵³ ⁶²	Armah HB...Perepletchikov AM	19523243	2009
15	Plasma chromogranin a in patients with inflammatory bowel disease. ⁵³ ⁶²	Sciola V...Piodi L	19090560	2009
16	Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. ⁵³ ⁶²	Srivastava A...Hornick JL	19065104	2009
17	Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway. ⁵³ ⁶²	Pinchot SN...Chen H	19245907	2009
18	The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome. ⁵³ ⁶²	Sidhu R...Sanders DS	19337629	2009
19	Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. ⁵³ ⁶²	Adler JT...Chen H	19030935	2009
20	Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. ⁵³ ⁶²	van Hoek M...Feelders RA	19017754	2009
21	Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary. ⁵³ ⁶²	Rabban JT...Zaloudek CJ	19047909	2009
22	Gastric-and-intestinal mixed endocrine cell phenotypic expression of carcinoid tumors in the rectum. ⁵³ ⁶²	Hirata Y...Joh T	19082450	2009
23	Single brain metastasis from a minute, well differentiated, but invading beyond the tunica muscularis mucosa rectal carcinoid. ⁵³ ⁶²	El Ali Z...Grzymislawski M	19402375	2009
24	Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors. ⁵³ ⁶²	Korse CM...Taal BG	18840995	2009
25	Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics. ⁵³ ⁶²	Bubanovic G...Franjevic A	19149223	2008
26	Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. ⁵³ ⁶²	Khan MU...Coleman RE	19088697	2008
27	Metastatic atypical carcinoid tumor of the inferior rectus muscle. ⁵³ ⁶²	Kiratli H...Yildiz ZI	19033849	2008
28	Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor. ⁵³ ⁶²	Pritchard DM...Varro A	18719002	2008
29	Tachykinins in endocrine tumors and the carcinoid syndrome. ⁵³ ⁶²	Cunningham JL...Stridsberg M	18524798	2008
30	Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth. ⁵³ ⁶²	Fujiki K...Chung DC	18655788	2008
31	Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors. ⁵³ ⁶²	Pinchot SN...Chen H	18516757	2008
32	Amyloid precursor-like protein 1 is differentially upregulated in neuroendocrine tumours of the gastrointestinal tract. ⁵³ ⁶²	Arvidsson Y...Nilsson O	18430897	2008
33	Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. ⁵³ ⁶²	Stridsberg M...Janson ET	18448176	2008
34	Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors. ⁵³ ⁶²	Namwongprom S...Boonyaprapa S	18535873	2008
35	Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogs. ⁵³ ⁶²	Debono M...Newell-Price J	18303072	2008
36	Wild-type and splice-variant secretin receptors in lung cancer: overexpression in carcinoid tumors and peritumoral lung tissue. ⁵³ ⁶²	Korner MU...Reubi JC	18223557	2008
37	CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients. ⁵³ ⁶²	Vikman S...Totterman TH	17717663	2008
38	Germ cell origin of testicular carcinoid tumors. ⁵³ ⁶²	Abbosh PH...Cheng L	18316560	2008
39	Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. ⁵³ ⁶²	Yao JC...Ajani JA	18323556	2008
40	Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors. ⁵³ ⁶²	Kidd M...Modlin IM	18224665	2008
41	Multiple gastric carcinoids associated with parietal cell hyperplasia: intraoperative detection with a radiolabeled somatostatin analog. ⁵³ ⁶²	Hosoya Y...Yasuda Y	18595020	2008
42	Bronchopulmonary carcinoid: phenotype and long-term outcome in a single-institution series of Italian patients. ⁵³ ⁶²	Rugge M...Rea F	18172265	2008
43	[Somatostatin analogues in the treatment of carcinoid]. ⁵³ ⁶²	Bednarikova M...Vyzula R	18578378	2008
44	[Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up]. ⁵³ ⁶²	Igaz P...Tulassay Z	18048114	2007
45	Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue. ⁵³ ⁶²	Manfredi S...Bretagne JF	18049175	2007
46	Tailored intermittent therapy of carcinoid. ⁵³ ⁶²	Kinova S...Koren M	18019702	2007
47	Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. ⁵³ ⁶²	Greenblatt DY...Chen H	17766653	2007
48	Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-beta1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1. ⁵³ ⁶²	Kidd M...Mane SM	17469181	2007
49	Peptide YY producing strumal carcinoid of the ovary as the cause of severe constipation with contralateral epithelial ovarian cancer. ⁵³ ⁶²	Kawano K...Kamura T	17578375	2007
50	Molecular targeted therapy for neuroendocrine tumors. ⁵³ ⁶²	Yao JC...Hoff PM	17548041	2007

Sources

Genes for Carcinoid Tumors, Intestinal

Genes related to Carcinoid Tumors, Intestinal (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NKX2-1	NK2 Homeobox 1	Protein Coding	16.42	Novoseek inferred ⁵³	11679943 19065104 15716236 (more) 12167104 15257545 11957142 19047909 9950155 10757334 18316560 19661786 15084379 17099078 8814700 11790979
2	ENO2	Enolase 2	Protein Coding	14.61	Novoseek inferred ⁵³	1723678 1477975 12190042 (more) 2279307 20504634 2067996 10522793 8691671 9253344 16699293 8027395 15723688 8869990 1656682 16673117 18019702 11890336 18172265
3	CHGA	Chromogranin A	Protein Coding	11.18	Novoseek inferred ⁵³	15757862 16432362 1856109 (more) 18535873 11579679 12687271 7599788 15015613 9891437 17922062 1313391 1702700 7891024 9825477 7720675 15551743 17438105 10953292 2316306 9877088 8208366 16086820 8308469 17163401 8813468 1381269 15177946 11762355 10697270 8837344 1854504 19090560 12144588 7607625 9610384 9693933 10469401 11204811 14651212 12851216 15058016 15899778 16840918 16955307 17146740 18516757 20504634 2109298 11342785 10511466 7503727 7515371 1656682 18448176 16673117 16282961 15621135 16422177 15644774 15104570 11394892 10473967 9253344 8869990 1341076 2047545 15648553 11762356 11021834 10496103 9417686 9230910 8767675 8601531 8381246 19088697 18524798 16502410 2222401 2166332 18048114 17766705 15906087 14713258 12842744 12771991 11790979 10398086 10629629 9296223 8640896 7984507 19402375 18840995 12543171 9852066 1304116 19337629 19224408
4	NOTCH1	Notch Receptor 1	Protein Coding	10.92	Novoseek inferred ⁵³	16160079 16360401 17766653 (more) 19030935 17522241
5	SST	Somatostatin	Protein Coding	10.9	Novoseek inferred ⁵³	9002775 7574789 18049175 (more) 9622077 7804439 1351720 18303072 11888987 1686137 19845567 8491220 1525756 1968753 15763700 11159212 19017754 15358337 15801004 8854840 8383865 1713051 18048114 12190042 9484822 8653698 7833144 7935635 1424169 10847473 9002774 9068482 1693375 2250512 8094238 7953441 8744192 11244329 12431842 8839899 8667061 7583974 1475626 19819594 18595020 17286235 17021482 15258554 9338023 9156050 8935599 8820376 8234912 8223776 8462029 1304116 1357826 8391830 2168286 8780551 2170840 20105920 17036195 18578378 18224665 15966194 1978946 14713257 11790981 11568027 10954763 9113314 7908199 8267450 1355584 1597726 2125001 1972187 20130865 20075713 12657865 11790979 11182566 11095353 9829380 9391539 9205872 8925846 8847018 8624794 7714118 15153445 12658727 12472080 10022452 9745411 9710364 9681860 9466486 1655997
6	GAST	Gastrin	Protein Coding	10.52	Novoseek inferred ⁵³	9465604 2049096 9752879 (more) 8204017 18719002 15706430 1551550 19918579 8372237 8835905 8182917 2237765 7953441 1925122 8323752 9786876 10378509 15161793 8604810 7606834 7859587 8125073 1404986 1871900 19082450 17382264 17059512 16495905 14686708 11472562 10461361 10461358 7859584 15723688 11742188 9071147 9030465 17391627 14687136 12842744 10964325 7762739 1374135 1697548 15846300 10422189 10604115 9303615 7479353 2125001 9287968 8920678 8266771 1646213 2171015 12270941 11274882 12725316 10365076 8667631 1590318 12702965 12946486 16950763
7	SYP	Synaptophysin	Protein Coding	10.5	Novoseek inferred ⁵³	15551743 10469401 11433616 (more) 14651212 15899778 18430897 18316560 1664142 12543171 11914632 11342785 7959661 7522390 16673117 15701827 15086297 11557784 8640896 19523243 15774214 14686708 7546678 2168288 15648553 11021834 8767675 19033849 16422177 15644774 12458898 8869990 2166332 17255771 16830392 15966515 1411400 19224408 16449819 20504634 2109298 2067996 9744317
8	MEN1	Menin 1	Protein Coding	9.39	Novoseek inferred ⁵³	16594911 10378509 16465412 (more) 9935177 10548885 14633735 11274644 14567464 10423035 11790979
9	CHGB	Chromogranin B	Protein Coding	8.43	Novoseek inferred ⁵³	7891024 9891437 7599788 (more) 1856109 15015613 10697270 18448176 1313391 7515371
10	SSTR2	Somatostatin Receptor 2	Protein Coding	8.06	Novoseek inferred ⁵³	9622077 12734860 8653698 (more) 8132773 8813459 16508627 9606281 8012966 9484822